GlassScriptPhysician profile
David Mann Kaplan
NPI 1134208994
$4,988.86
in general payments reported to CMS, 2019-2025
27 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $217 · 2021: $362 · 2022: $695 · 2023: $1,017 · 2024: $1,291 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,602.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $894.92 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Indivior INC. | $658.45 | 2019-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $567.58 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Braeburn INC. | $477.47 | 2023-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $459.93 | 2022-2025 | Caplyta |
| Lundbeck LLC | $396.05 | 2022-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $252.46 | 2021-2025 | |
| Orexo US, INC. | $199.58 | 2019-2022 | |
| Tris Pharma INC | $191.69 | 2022-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $190.41 | 2021-2025 | |
| Corium, LLC | $118.02 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $110.95 | 2022-2025 | Qelbree, Qelbree |
| Uswm, LLC | $98.87 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $78.32 | 2019 | |
| Ironshore Pharmaceuticals INC. | $46.88 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35.80 | 2023-2025 | Uzedy |
| Vanda Pharmaceuticals INC. | $30.20 | 2024-2025 | Fanapt, Hetlioz |
| Mdd US Operations, LLC | $23.52 | 2020 | |
| Pulmonx Corporation | $23.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.07 | 2025 | Cobenfy |
| Sanofi-Aventis U.S. LLC | $20.89 | 2020 | |
| Neos Therapeutics, LP | $17.89 | 2024 | Adzenys Xr-Odt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.68 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.95 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $14.27 | 2024 | Trintellix |
| Amarin Pharma, INC. | $13.54 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.08 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.